Secondary Logo

Journal Logo

September 1, 2022 - Volume 91 - Issue 1

  • Paul A. Volberding, MD
    William A. Blattner, MD
  • 1525-4135
  • 1077-9450
  • 15 issues per year
  • Infectious Diseases 57/94
    Immunology 107/161
  • 3.771
Harnessing Implementation Science to Inform Strategies for Ending the HIV Epidemic in the United States Guest Editors: Nanette Benbow, MAS; Dennis H. Li, PhD; Brian Mustanski, PhD and Justin D. Smith, PhD
Published July 1, 2022
Other Supplements

Current Issue Highlights


Sexually Transmitted Infections Among Men and Transgender Women Using HIV Pre-exposure Prophylaxis in a Large Integrated Health System—A Cohort Study

Hechter, Rulin C.; Bruxvoort, Katia J.; Zhou, Hui; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 91(1):1-8, September 1, 2022.

HIV Incidence in Botswana Rural Communities With High Antiretroviral Treatment Coverage: Results From the Botswana Combination Prevention Project, 2013–2017

Ussery, Faith; Bachanas, Pamela; Alwano, Mary Grace; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 91(1):9-16, September 1, 2022.


Brief Report: Quantifiable Plasma Tenofovir Among South African Women Using Daily Oral Pre-exposure Prophylaxis During the ECHO Trial

Beesham, Ivana; Mansoor, Leila E.; Joseph Davey, Dvora L.; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 91(1):26-30, September 1, 2022.

Employment as HIV Prevention: An Employment Support Intervention for Adolescent Men Who Have Sex With Men and Adolescent Transgender Women of Color

Hill, Brandon J.; Motley, Darnell N.; Rosentel, Kris; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 91(1):31-38, September 1, 2022.


HIV Pre-exposure Prophylaxis Uptake and Continuation Among Key Populations in Cameroon: Lessons Learned From the CHAMP Program

Ndenkeh, Jackson Jr Nforbewing; Bowring, Anna L.; Njindam, Iliassou Mfochive; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 91(1):39-46, September 1, 2022.

A Longitudinal Mixed-Methods Examination of Positive Health Check: Implementation Results From a Type 1 Effectiveness-Implementation Hybrid Trial

Garner, Bryan R.; Burrus, Olivia; Ortiz, Alexa; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 91(1):47-57, September 1, 2022.


Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine

Molina, Jean-Michel; Yazdanpanah, Yazdan; Afani Saud, Alejandro; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 91(1):68-72, September 1, 2022.

Brief Report: Evaluation of Inflammation and Atherogenesis Biomarkers Through 148 Weeks Postswitch to Dolutegravir and Rilpivirine in SWORD-1/SWORD-2

Llibre, Josep M.; López Cortés, Luis Fernando; Aylott, Alicia; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 91(1):73-78, September 1, 2022.



`